Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst ...
With the FDA shutting down its key revenue stream, Hims faces a tough road ahead--can it justify its valuation?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback